Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial

Patients with schizophrenia have exceedingly high rates of metabolic comorbidity including type 2 diabetes and lose 15–20 years of life due to cardiovascular diseases, with early accrual of cardiometabolic disease. In this study, thirty overweight or obese (Body Mass Index (BMI) > 25) participant...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwal, Sri Mahavir, Panda, Roshni, Costa-Dookhan, Kenya A., MacKenzie, Nicole E., Treen, Quinn Casuccio, Caravaggio, Fernando, Hashim, Eyesha, Leung, General, Kirpalani, Anish, Matheson, Kelly, Chintoh, Araba F., Kramer, Caroline K., Voineskos, Aristotle N., Graff-Guerrero, Ariel, Remington, Gary J., Hahn, Margaret K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046796/
https://www.ncbi.nlm.nih.gov/pubmed/33854039
http://dx.doi.org/10.1038/s41398-021-01338-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046796/
https://www.ncbi.nlm.nih.gov/pubmed/33854039
http://dx.doi.org/10.1038/s41398-021-01338-2

Ejemplares similares